The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

Jan. 31, 2025 – The FDA has approved a new non-opioid oral drug for acute pain in adults. It is the first new class of non-opioid pain medicine approved in over 20 years, providing effective ...

Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

2025 – The FDA has approved a new pill to treat adults with ... or a placebo plus chemoimmunotherapy. The new drug combination reduced the risk of disease progression or death by 27%, with ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

Federal officials approved a new non-opioid painkiller ... acting director of the FDA’s Center for Drug Evaluation and Research. The new class of drugs, known as non-opioid analgesics ...

The FDA on Thursday approved Journavx, the first new type of pain reliever to be approved in more than two decades. The FDA said the drug was tested in two trials with more than 800 participants ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...